Gastrin
From PeptidePlaza, the free peptide reference · Entry #1005 · Metabolic · Sources fetched 2026-09-10 · Editorial standards
Gastrin is a metabolic research peptide. Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.
Gastrin is an endogenous human peptide, specifically a 17-residue peptide with the sequence QGPWLEEEEEAYGWMDF. Its primary mechanism of action involves stimulating the stomach mucosa to produce and secrete hydrochloric acid, and the pancreas to secrete its digestive enzymes. Additionally, gastrin stimulates smooth muscle contraction and enhances blood circulation and water secretion in the stomach and intestine. Gastrin is currently an investigational compound. Research on gastrin frequently focuses on its physiological roles, its involvement in upper gastrointestinal cancers, and diagnostic measurements.
1 Mechanism of action
Gastrin stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete its digestive enzymes. It also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine
2 Chemical and physical properties
| CAS number | 9002-76-0 |
|---|---|
| Molar mass | 2116.2 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
2.1 Amino acid sequence
QGPWLEEEEEAYGWMDF
3 Research studies (8)
- Physiology, Gastrin
(2026) - Gastrin and upper GI cancers
Current opinion in pharmacology (2016) · Review - The G cell
Annual review of physiology (1997) · Review - Pitfalls in diagnostic gastrin measurements
Clinical chemistry (2012) · Review - Phylogeny of the cholecystokinin/gastrin family
Frontiers in neuroendocrinology (1998) · Review - [Gastrin]
Zeitschrift fur Gastroenterologie (1978) - [Gastrin]
Annali dell'Istituto superiore di sanita (1975) - Gastrin and cancer: a review
Cancer letters (2006) · Review
4 Safety and risk profile
4.1 Regulatory status
Gastrin is currently classified as Investigational. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
5 Frequently asked questions
- What is gastrin?
- Gastrin is an endogenous human peptide composed of 17 amino acid residues. It plays a crucial role in the digestive system by stimulating various functions in the stomach and pancreas.
- How does gastrin work?
- Gastrin works by stimulating the stomach lining to produce and secrete hydrochloric acid. It also prompts the pancreas to release its digestive enzymes, stimulates smooth muscle contraction, and increases blood circulation and water secretion in the stomach and intestine.
- What is gastrin studied for?
- Gastrin is studied for its physiological functions, its potential role in upper gastrointestinal cancers, and for diagnostic measurements related to its levels in the body. Research also explores its evolutionary history within the cholecystokinin/gastrin family.
- Is gastrin FDA approved?
- No, gastrin is currently an investigational compound and is not FDA approved for any specific medical use.
6 References
- Gastrin — compound summary PubChem. View source
- Gastrin — molecule record ChEMBL. View source
- Gastrin — protein entry UniProt. View source
- Gastrin — published literature (17,075 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Gastrin.
Shares blood and stimulates pharmacology
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Shares increases and secretion pharmacology
A long-acting GLP-1 analog distinguished by its C18 fatty diacid chain, enabling albumin binding and a half-life of ~7 days. One of the most clinically studied peptides in modern metabolic research.
Shares increases and blood pharmacology
A single amino acid substitution turns GLP-2 from a 7-minute hormone into a drug that regrows intestinal villi. The only approved peptide that makes the gut physically bigger.
Shares secretion and increases pharmacology
An oxyntomodulin-based dual agonist and the first GLP-1/glucagon co-agonist approved anywhere in the world — cleared in China for weight management in 2025.
Also metabolic
The GLP-1 that proved the class. A C16 palmitoyl chain gave native GLP-1 a 13-hour half-life instead of two minutes — and produced the first cardiovascular outcome data for the family.
Also metabolic
A 39-amino acid synthetic peptide that simultaneously activates GIP and GLP-1 receptors. Demonstrated greater weight loss than any approved single-agonist in clinical trials.